Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...
Incyte today announced that the U.S. Food and Drug Administration has approved Pemazyre ®, a selective fibroblast growth factor receptor inhibitor, for the treatment of adults with relapsed or ...
Opportunities in the Global Refractory Follicular Lymphoma Diagnostics Market include the growing need for MRD monitoring and liquid biopsies, driven by the rise in hematologic malignancies. The surge ...
Cervical lymphadenopathy presents a shared anatomic challenge for clinicians, yet it serves as the divergent starting point ...
Patients with Waldenström Non-Hodgkin lymphoma in the U.S. achieved durable complete responses of up to 15 months using a chemotherapy-free CD19 CAR-NK (chimeric antigen receptor natural killer) cell ...
New three-year follow-up results from the TRANSCEND FL trial show that patients with relapsed or refractory follicular lymphoma can achieve durable, multi-year remission with chimeric antigen receptor ...
The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on ...
Tonsillar lymphoma is a rare but highly treatable throat cancer that affects the tonsils. The most common treatment for this type of lymphoma is chemotherapy. Radiation and surgery to remove the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results